Patents by Inventor Gary A. Flynn

Gary A. Flynn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220281996
    Abstract: The invention provides compositions and methods for binding and inhibiting renalase. In one embodiment, the renalase binding molecule inhibits renalase activity. Thus, in diseases and conditions where a reduction of renalase activity is beneficial, such inhibitory renalase binding molecules act as therapeutics.
    Type: Application
    Filed: May 9, 2022
    Publication date: September 8, 2022
    Inventors: Gary Desir, Abigail Hunt, Jessica O-Rear, Peter Flynn
  • Patent number: 11370846
    Abstract: The invention provides compositions and methods for binding and inhibiting renalase. In one embodiment, the renalase binding molecule inhibits renalase activity. Thus, in diseases and conditions where a reduction of renalase activity is beneficial, such inhibitory renalase binding molecules act as therapeutics.
    Type: Grant
    Filed: April 14, 2020
    Date of Patent: June 28, 2022
    Assignee: Yale University
    Inventors: Gary Desir, Abigail Hunt, Jessica O-Rear, Peter Flynn
  • Publication number: 20220177891
    Abstract: Method of treating cancer, such as a metastatic cancer, with inhibitors of homeodomain interacting protein kinase 4 (HIPK4) are provided. Related therapeutic compositions are also disclosed.
    Type: Application
    Filed: February 19, 2020
    Publication date: June 9, 2022
    Applicants: Board of Regents, The University of Texas System, Vibliome Therapeutics, LLC
    Inventors: Qiang SHEN, Gary A. FLYNN
  • Publication number: 20220106303
    Abstract: Provided herein are protein kinase inhibitors, which, in one aspect are selective inhibitors of HipK4. Pharmaceutical compositions and medical uses for the disclosed inhibitors are also provided.
    Type: Application
    Filed: September 30, 2021
    Publication date: April 7, 2022
    Inventors: Gary A. Flynn, Ashok Bajji, Khoi Huynh
  • Publication number: 20210070715
    Abstract: Compounds having activity as inhibitors of ALK2 kinase and/or JAK2 kinase are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, X, z and A are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: July 15, 2020
    Publication date: March 11, 2021
    Inventors: Alexis Mollard, Steven L. Warner, Gary A. Flynn, Hariprasad Vankayalapati, David J. Bearss
  • Patent number: 10752594
    Abstract: Compounds having activity as inhibitors of ALK2 kinase and/or JAK2 kinase are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, X, z and A are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: August 25, 2020
    Assignee: SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC.
    Inventors: Alexis Mollard, Steven L. Warner, Gary A. Flynn, Hariprasad Vankayalapati, David J. Bearss
  • Publication number: 20190119221
    Abstract: Compounds having activity as inhibitors of ALK2 kinase and/or JAK2 kinase are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, X, z and A are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: December 19, 2018
    Publication date: April 25, 2019
    Inventors: Alexis Mollard, Steven L. Warner, Gary A. Flynn, Hariprasad Vankayalapati, David J. Bearss
  • Patent number: 10202356
    Abstract: Compounds having activity as inhibitors of ALK2 kinase and/or JAK2 kinase are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, X, z and A are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: February 12, 2019
    Assignee: Tolero Pharmaceuticals, Inc.
    Inventors: Alexis Mollard, Steven L. Warner, Gary A. Flynn, Hariprasad Vankayalapati, David J. Bearss
  • Patent number: 9981901
    Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: May 29, 2018
    Assignee: FOSUN ORINOVE PHARMATECH, INC.
    Inventors: John B. Patterson, David G. Lonergan, Gary A. Flynn, Qingping Zeng, Peter V. Pallai
  • Publication number: 20180125848
    Abstract: The present disclosure relates to compounds of the Formula (I): and pharmaceutically acceptable salts, as kinase modulators, compatible with the Type-II inhibition of kinases.
    Type: Application
    Filed: November 2, 2017
    Publication date: May 10, 2018
    Inventor: Gary A. Flynn
  • Patent number: 9833455
    Abstract: The present disclosure relates to compounds of the Formula (I): and pharmaceutically acceptable salts, as kinase modulators, compatible with the Type-II inhibition of kinases.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: December 5, 2017
    Assignee: Spacefill Enterprises LLC
    Inventor: Gary A. Flynn
  • Patent number: 9714247
    Abstract: Kinase with inhibitory activity against kinases disposed in multiple signaling pathways and their therapeutic uses.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: July 25, 2017
    Assignees: Tolero Pharmaceuticals, Inc., Mannkind Corporation
    Inventors: Qingping Zeng, Mary Faris, Alexis Mollard, Steven L. Warner, Gary A. Flynn
  • Publication number: 20170152206
    Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
    Type: Application
    Filed: November 18, 2016
    Publication date: June 1, 2017
    Inventors: John B. Patterson, David G. Lonergan, Gary A. Flynn, Qingping Zeng, Peter V. Pallai
  • Publication number: 20170107215
    Abstract: Kinase with inhibitory activity against kinases disposed in multiple signaling pathways and their therapeutic uses.
    Type: Application
    Filed: September 26, 2016
    Publication date: April 20, 2017
    Inventors: Qingping Zeng, Mary Faris, Alexis Mollard, Steven L. Warner, Gary A. Flynn
  • Patent number: 9546149
    Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: January 17, 2017
    Assignee: MannKind Corporation
    Inventors: John B. Patterson, David G. Lonergan, Gary A. Flynn, Qingpeng Zeng, Peter V. Pallai
  • Patent number: 9493454
    Abstract: Kinase with inhibitory activity against kinases disposed in multiple signaling pathways and their therapeutic uses.
    Type: Grant
    Filed: September 25, 2013
    Date of Patent: November 15, 2016
    Assignees: Tolero Pharmaceuticals, Inc., Mannkind Corporation
    Inventors: Qingping Zeng, Mary Faris, Alexis Mollard, Steven L. Warner, Gary A. Flynn
  • Publication number: 20160303128
    Abstract: The present disclosure relates to compounds of the Formula (I): and pharmaceutically acceptable salts, as kinase modulators, compatible with the Type-II inhibition of kinases.
    Type: Application
    Filed: November 12, 2015
    Publication date: October 20, 2016
    Inventor: Gary A. Flynn
  • Publication number: 20160214944
    Abstract: Compounds having activity as inhibitors of ALK2 kinase and/or JAK2 kinase are disclosed. The compounds have the following structure (I): [FORMULA SHOULD BE INSERTED HERE] including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, X, z and A are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: March 13, 2014
    Publication date: July 28, 2016
    Inventors: Alexis MOLLARD, Steven L. WARNER, Gary A. FLYNN, Hariprasad VANKAYALAPATI, David J. BEARSS
  • Publication number: 20160168116
    Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
    Type: Application
    Filed: December 15, 2015
    Publication date: June 16, 2016
    Inventors: John B. Patterson, David G. Lonergan, Gary A. Flynn, Qingpeng Zeng, Peter V. Pallai
  • Patent number: 9248131
    Abstract: Compounds, including 3-carboxy aryl sulfonamide compounds, which agonize or antagonize aquaporin channels and methods of using them to treat disorders or diseases mediated by aquaporins.
    Type: Grant
    Filed: April 3, 2015
    Date of Patent: February 2, 2016
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
    Inventors: Gary A. Flynn, Andrea J. Yool, Elton Rodrigues Migliati, Leslie S. Ritter